Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on BioMarin to $125 from $120 and keeps a Buy rating on the shares after the company reported Voxzogo FY22 revenue of about $169M, at the upper end of the guidance established in Q3, and also reiterated its commitment to GAAP profitability and unveiled preliminary clinical data on BMN255 and BMN331.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin announces data from follow up from Phase 3 GENEr8-1 study of ROCTAVIAN
- BioMarin price target raised to $200, added to ‘US 1 List’ at BofA
- BioMarin’s application for Voxzogo in achondroplasia validated by EMA
- BioMarin price raises ‘more aggressive’ in 2023, says Piper Sandler
- BioMarin price target raised to $120 from $100 at Jefferies